CompletedN/Aketamine

Chart Review of Patients Undergoing Ketamine Treatments for Depression

NCT ID

NCT07099235

Target Enrollment

250 participants

Start Date

2022-04-01

Est. Completion

2025-06-29

About This Study

The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.

Conditions Studied

Depression - Major Depressive Disorder

Interventions

•ketamine hydrochloride

Eligibility

Age:18 Years - N/A

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

* Age ≥ 18
* Able to provide informed consent
* Patient diagnosed with treatment-resistant depression
* Outpatient recommended and approved by psychiatrist for ketamine treatment
* Individuals who have previously received ECT, rTMS or any other neuromodulation can also receive ketamine

Exclusion Criteria:

* History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist
* Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment
* History of substance misuse and/or dependence, including chronic alcohol abuse
* Previous ketamine use
* Acute dementia/delirium
* Pregnancy/breastfeeding
* Previous sensitivity to ketamine or related compounds
* Unstable medical condition which may require anesthesia consult
* History of elevated intracranial pressure or cerebrovascular accident
* Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)

Study Locations (1)

Ontario Ketamine and Infusion Centre - Toronto Site